November 22, 2026
Stainless steel surgical instruments

Surgical instruments of the kind used in orthopedic and general surgery procedures. Source: Wikimedia Commons, آرمین; license: CC0.

Largo-based CONMED posted Q3 2026 sales of $335.6 million as it exits GI lines; organic growth reached 6.7%, margins jumped and 2026 guidance narrowed.

Quick Answer: CONMED, the Largo-based surgical device maker, reported third-quarter 2026 net sales of $335.6 million, down 0.7% from a year earlier because it is exiting its gastroenterology lines. Organic constant-currency sales rose 6.7%. GAAP earnings rose to $0.66 a diluted share from $0.09, and on October 28, 2026, the company tightened its full-year sales outlook to $1.360 billion to $1.366 billion.

CONMED Corporation (NYSE: CNMD) is one of the largest publicly traded manufacturers based in Pinellas County. Its third-quarter 2026 report looks soft on the surface and much stronger underneath. Total sales slipped slightly because the company is deliberately leaving the gastroenterology (GI) business. The products it is keeping, including orthopedic implants, sports medicine devices, the AirSeal insufflation system and Buffalo Filter smoke evacuation, grew at a mid-to-high single-digit pace. Gross margin rose more than seven percentage points.

How did CONMED perform in Q3 2026?

CONMED reported net sales of $335.6 million for the three months ended September 30, 2026, compared with $337.9 million in the third quarter of 2025. That is a decline of 0.7% as reported and 0.8% in constant currency. Excluding the GI product lines the company is exiting, organic constant-currency sales grew 6.7%.

Profitability improved more sharply. Gross profit was $189.1 million, a 56.4% gross margin, up from $166.1 million and 49.2% a year earlier. Operating income tripled to $37.1 million from $11.9 million, and operating margin rose to 11.1% from 3.5%. Net income was $19.8 million, or $0.66 per diluted share, compared with $2.9 million, or $0.09 per diluted share, in the third quarter of 2025.

On an adjusted basis, which excludes items such as divestiture gains and losses, product rationalization charges and executive transition costs, the picture is flatter. Adjusted net income was $31.4 million, compared with $33.4 million. Adjusted diluted earnings per share were $1.04, down 3.2% from $1.08. Adjusted operating margin edged up to 15.4% from 15.1%. Adjusted EBITDA rose to $67.9 million, or 20.2% of sales, from $65.6 million, or 19.4%.

Metric Q3 2026 Q3 2025
Net sales $335.6 million $337.9 million
Organic constant-currency growth 6.7% n/a
Gross margin 56.4% 49.2%
Operating income $37.1 million (11.1%) $11.9 million (3.5%)
Net income $19.8 million $2.9 million
GAAP diluted EPS $0.66 $0.09
Adjusted diluted EPS $1.04 $1.08
Adjusted EBITDA $67.9 million (20.2%) $65.6 million (19.4%)

President and CEO Patrick J. Beyer said in the release that the quarter’s organic constant-currency growth “was consistent with our expectations.” He tied the outlook to a sharper focus on the company’s core markets following its portfolio changes.

Why did reported sales fall while organic sales grew?

The gap is almost entirely the GI exit. In December 2025, CONMED announced it would leave its gastroenterology product lines as part of what it calls portfolio optimization. Under the 2025 Form 10-K, that included ending its distribution agreement with W.L. Gore & Associates for the Gore VIABIL biliary stent, effective January 1, 2026, and exiting the remaining GI products. On the third-quarter call, management said it now assumes about $20 million of GI revenue for all of 2026, with about $3.7 million of that in the fourth quarter. The company says the exits reduce full-year reported sales growth by roughly 6.7 to 6.8 percentage points.

The effect shows most clearly in the U.S. numbers. Domestic sales fell 11.0% as reported, to $172.7 million from $194.0 million, but rose 0.8% on an organic constant-currency basis. International sales climbed 13.1% as reported, to $162.9 million from $143.9 million, and 13.8% organically. International customers accounted for about 48.5% of third-quarter sales, compared with about 44% of 2025 net sales disclosed in the annual report.

How did CONMED’s orthopedic and general surgery segments do?

CONMED reports two segments. Orthopedic Surgery includes sports medicine implants, foot-and-ankle products and powered surgical instruments. General Surgery includes AirSeal, Buffalo Filter, electrosurgery, endomechanical products and the GI lines being wound down. In 2025, orthopedics made up 42% of net sales and general surgery 58%, according to the 10-K. In the third quarter of 2026, orthopedics rose to about 44% of sales.

Segment / category Q3 2026 sales Reported change Organic constant-currency change
Orthopedic Surgery $148.8 million +7.7% +7.2%
General Surgery $186.7 million -6.5% +6.4%
Domestic (U.S.) $172.7 million -11.0% +0.8%
International $162.9 million +13.1% +13.8%
Single-use products $285.7 million -1.2% n/a
Capital products $49.8 million +2.2% n/a

What drove orthopedic growth?

Orthopedic sales rose 7.7% as reported, to $148.8 million, and 7.2% organically. The growth came from outside the United States. On the earnings call, management said international orthopedic sales grew 12.7% while U.S. orthopedic sales fell 1.7% during a commercial restructuring of the domestic sales organization. Executives said they expect U.S. orthopedics to return to growth by the end of 2026 or in the first half of 2027.

The product management highlighted most was BioBrace, a biologic implant used to reinforce soft-tissue repairs. Executives cited a 94% healing rate in high-risk rotator cuff repairs and said the product is approved in Brazil, Canada and several other international markets. They also said studies are under way in the knee and Achilles.

What drove general surgery growth?

General Surgery sales fell 6.5% as reported, to $186.7 million, but rose 6.4% organically. Management said AirSeal grew in the high-single-digit to low-double-digit range, supported by steady sales of disposables and strong international capital equipment sales. In July 2026, CONMED announced that the AirSeal Robotic Solution is indicated for use with Intuitive’s 8 mm hex cannulas on the da Vinci 5 surgical robot. Executives estimated that AirSeal is used in only 6% to 7% of the more than 3 million laparoscopic procedures performed in the U.S. each year.

Buffalo Filter’s direct smoke-evacuation sales also grew in the high-single-digit to low-double-digit range. Original-equipment-manufacturer (OEM) sales declined, which management described as a more variable business it is de-emphasizing in favor of higher-margin direct sales. The company said 23 states now have laws requiring smoke-free operating rooms, covering roughly 60% of the U.S. population.

What is CONMED’s updated 2026 guidance?

On October 28, 2026, CONMED narrowed its full-year 2026 sales range to $1.360 billion to $1.366 billion, from the $1.358 billion to $1.373 billion range it gave on July 29. It raised the bottom of its adjusted EPS range, which is now $4.54 to $4.61, up from $4.48 to $4.60. Organic constant-currency growth is now expected at 5.0% to 5.5%, compared with 5.0% to 6.0% previously.

2026 guidance item Updated Oct. 28 Prior (July 29)
Net sales $1.360B to $1.366B $1.358B to $1.373B
Reported sales growth -1.1% to -0.6% -1.2% to -0.1%
Organic constant-currency growth 5.0% to 5.5% 5.0% to 6.0%
Adjusted diluted EPS $4.54 to $4.61 $4.48 to $4.60
Free cash flow (call commentary) About $115 million n/a

Through nine months, CONMED reported $996.1 million in sales and adjusted EPS of $3.31. Based on those figures, the full-year guidance implies fourth-quarter sales of about $364 million to $370 million and fourth-quarter adjusted EPS of roughly $1.23 to $1.30. For comparison, full-year 2025 net sales were $1.375 billion, so the guidance midpoint is about 1% below last year on a reported basis even with mid-single-digit organic growth.

Management repeated its estimate that tariffs will cost about $0.35 per share in 2026, excluding any refunds, and cautioned that conditions could change. Chief Financial Officer John Gallagher said the GI exit cost more than $0.45 per share in 2026 and that this headwind should not recur in 2027. The company declined to give 2027 guidance and said it would do so on its fourth-quarter call.

What do the nine-month results show?

For the first nine months of 2026, sales were $996.1 million, down 0.5% as reported and up 5.0% organically. Orthopedic sales rose 7.6% to $448.8 million. General Surgery sales fell 6.3% to $547.3 million but rose 4.0% organically. Net income nearly doubled, to $56.7 million from $30.3 million, and GAAP diluted EPS rose to $1.87 from $0.97. Adjusted diluted EPS rose to $3.31 from $3.17. Nine-month gross margin was 57.2%, compared with 53.1%.

How is CONMED handling its debt and cash?

According to the call, total debt was $815.9 million on September 30, 2026, down from $834.9 million at the end of 2025. During the year, CONMED used a new $450 million term loan and its revolving credit facility to repurchase $645.2 million of its $800 million in 2.25% convertible notes due June 2027. That refinancing raised borrowing costs. Third-quarter GAAP interest expense was $11.1 million, compared with $7.6 million a year earlier, and management guided to about $33.7 million in adjusted interest expense for 2026. Leverage stood at 2.7 times at quarter-end.

Third-quarter free cash flow was $46.4 million, down 3.6%. Through nine months, CONMED bought back about 1.2 million shares for $49.9 million and is targeting about $62 million for the full year. The diluted share count fell to 30.1 million from 31.1 million a year earlier, which helped per-share results.

What does CONMED’s Largo headquarters mean for Pinellas County?

CONMED’s corporate address is 11311 Concept Boulevard in Largo. In January 2021, the St. Pete Catalyst reported that the company had designated its Largo office as corporate headquarters. The company had been based in Utica, New York, where it was founded in 1970, and the Utica site remained open. At the time, the Catalyst reported about 850 employees in Largo out of roughly 3,300 worldwide. CONMED has not published a newer Largo headcount. Its 2025 10-K reports about 3,900 full-time employees companywide as of December 31, 2025, including about 2,400 in operations.

Largo is a manufacturing site, not just an office. The 10-K lists the Largo facility as a 278,000-square-foot property the company owns and identifies it as one of CONMED’s principal manufacturing facilities. It is second in size only to the company’s 500,000-square-foot owned plant in Utica. Other major sites include a leased 330,000-square-foot distribution center in Lithia Springs, Georgia, leased manufacturing space in Chihuahua, Mexico, and a distribution center in Brussels. The filing also notes that the Largo site was temporarily affected by Hurricane Milton.

CONMED snapshot Detail
Headquarters 11311 Concept Blvd., Largo, Pinellas County
Ticker NYSE: CNMD
Founded 1970, Utica, New York
President and CEO Patrick J. Beyer
CFO John Gallagher
Employees About 3,900 full-time (Dec. 31, 2025)
Largo facility 278,000 sq. ft., owned, principal manufacturing
2025 net sales / net income $1.375 billion / $47.1 million
Key brands BioBrace, Y-Knot, AirSeal, Buffalo Filter, Hall, Linvatec

The Largo connection goes back to the company’s orthopedic business. CONMED bought Linvatec from Bristol-Myers Squibb in 1997, and CONMED Linvatec remains one of the orthopedic brand names in its annual report. The company later expanded through acquisitions, including Buffalo Filter in 2019 and In2Bones and Biorez in 2022.

For the mid-Pinellas industrial corridor, CONMED is an example of high-value device manufacturing that sells to hospitals around the world. International customers now account for nearly half of quarterly revenue, and most of its sales come from single-use products that hospitals reorder steadily. In the third quarter, single-use products brought in $285.7 million of the $335.6 million total, about 85%. That kind of recurring demand tends to support steady factory employment more than one-time equipment sales do.

Brian’s Take

I look past the headline here. A 0.7% sales decline sounds like a stall, but CONMED chose to give up its GI business. The rest of the company grew 6.7%, and gross margin went from 49.2% to 56.4%. That is what a company looks like when it trades revenue for profitability. For a manufacturer with a 278,000-square-foot plant in Largo, a smaller business with better margins is generally a more durable one than a larger business with weaker margins.

Two things temper my view. First, U.S. orthopedic sales fell 1.7% while the domestic sales force was restructured. Growth abroad is welcome, but this company still needs its home market to grow. Second, refinancing the convertible notes made debt more expensive, with quarterly interest expense rising from $7.6 million to $11.1 million. Tariffs are also costing about $0.35 a share. None of these problems is fatal, but each one takes money that could otherwise go toward growth.

For Pinellas County, the bigger point is that CONMED is a real manufacturer that sells mostly consumable products to hospitals in many countries. Those are the employers that keep a county’s industrial base diversified beyond tourism and real estate. I will be watching whether the company’s next Largo headcount figure grows along with its margins.

Frequently Asked Questions

Where is CONMED headquartered?

CONMED’s corporate headquarters is at 11311 Concept Boulevard in Largo, Florida, in Pinellas County. It also owns a 278,000-square-foot principal manufacturing facility in Largo.

How much revenue did CONMED report for Q3 2026?

Net sales were $335.6 million for the quarter ended September 30, 2026. That was down 0.7% as reported but up 6.7% on an organic constant-currency basis, which excludes the GI lines the company is exiting.

What were CONMED’s Q3 2026 earnings per share?

GAAP diluted EPS was $0.66, up from $0.09 a year earlier. Adjusted diluted EPS was $1.04, compared with $1.08.

What is CONMED’s 2026 guidance?

As of October 28, 2026, CONMED expects net sales of $1.360 billion to $1.366 billion, organic constant-currency growth of 5.0% to 5.5% and adjusted diluted EPS of $4.54 to $4.61.

Why is CONMED exiting gastroenterology?

The company calls the move part of a portfolio optimization strategy to focus on its core orthopedic and general surgery markets. The exit included ending its Gore VIABIL stent distribution agreement on January 1, 2026.

Sources and Further Reading

  1. CONMED Corporation Reports Third Quarter 2026 Financial Results, Updates Full Year 2026 Guidance (Form 8-K, Exhibit 99) — U.S. Securities and Exchange Commission
  2. CONMED Corporation Annual Report on Form 10-K for the fiscal year ended December 31, 2025 — U.S. Securities and Exchange Commission
  3. CONMED Q3 2026 Earnings Call Transcript — TradingKey
  4. Nearly $1 billion public company shifts corporate headquarters to Largo — St. Pete Catalyst
  5. CONMED Corporation — Wikipedia

About Brian French

Brian French is a seasoned marketing professional and former financial executive with over 25 years of experience in understanding Florida's growth. He is a pioneer in AI marketing and developing digital authority.

Based in St. Petersburg for more than six years, Brian resided in the Old Northeast while operating from Central Avenue as a Vice President and Portfolio Manager with Merrill Lynch Private Investors. During this tenure, he served on a team managing a portfolio exceeding $50 billion, specializing in institutional strategy and asset management for one of the world's largest investment groups.

Today, Brian leverages this background in finance and his expertise to lead the Florida Authority Network (FAN).


The Florida Authority Network (FAN)

This website is a core asset of the Florida Authority Network, a proprietary digital ecosystem owned and operated by Brian French.

  • Objective: To establish dominant "Digital Authority" across Florida’s primary business sectors using advanced Generative Engine Optimization (GEO) and Answer Engine Optimization (AEO).
  • Purpose: The network serves as a sophisticated infrastructure for localized business news—including StPetersburgBusinessNews.com—designed to capture and influence AI-driven search results.
  • Strategy: By synchronizing a network of high-authority regional domains, Brian provides a platform that bridges the gap between traditional professional services and modern technical curation.